These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 26668268)

  • 61. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
    Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
    Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
    Halaban R; Zhang W; Bacchiocchi A; Cheng E; Parisi F; Ariyan S; Krauthammer M; McCusker JP; Kluger Y; Sznol M
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):190-200. PubMed ID: 20149136
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 65. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
    Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
    Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
    Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.
    Han Y; Fang J; Xiao Z; Deng J; Zhang M; Gu L
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):767-777. PubMed ID: 33389075
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.
    Klein RM; Higgins PJ
    Mol Cancer; 2011 Sep; 10():114. PubMed ID: 21917148
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
    Yoo G; Kim T; Chung C; Hwang DS; Lim DS
    Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
    Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
    Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma.
    Pisanu ME; Maugeri-Saccà M; Fattore L; Bruschini S; De Vitis C; Tabbì E; Bellei B; Migliano E; Kovacs D; Camera E; Picardo M; Jakopin Z; Cippitelli C; Bartolazzi A; Raffa S; Torrisi MR; Fulciniti F; Ascierto PA; Ciliberto G; Mancini R
    J Exp Clin Cancer Res; 2018 Dec; 37(1):318. PubMed ID: 30558661
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ.
    Ji J; Xu R; Zhang X; Han M; Xu Y; Wei Y; Ding K; Wang S; Bin Huang ; Chen A; Di Zhang ; Jiang Z; Xu S; Zhang Q; Li W; Ni S; Wang J; Li X
    Cell Death Dis; 2018 May; 9(5):517. PubMed ID: 29725063
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
    Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
    Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.